The American College of Obstetricians and Gynecologists hadn’t touched its menopause symptom guidance since 2014. On October 15, it did, and the update is bigger than a routine refresh. ACOG is calling it the most comprehensive guidance on managing menopause the organization has published to date, and it changes how doctors are told to think about one of the most common questions in women’s health: what to do about hot flashes, night sweats, sleep problems, and mood changes that show up around menopause.
This is a news summary of that guideline, not medical advice. What follows is what ACOG said, what independent outlets reported, and nothing more.
Why this guideline exists
ACOG’s own numbers explain why this isn’t a niche update. Between 50% and 92% of women going through menopause report vasomotor symptoms, the clinical term for hot flashes and night sweats. Between 16% and 66% of women in the U.S. report menopause-related sleep disruption. More than a third of perimenopausal and postmenopausal women worldwide report depressive symptoms. Natural menopause happens at an average age of 50 in the U.S., but symptoms can start years before a woman’s last period and continue for years after, according to ACOG.
“Perimenopause and menopause symptoms can be debilitating, interfering with women’s overall health, their ability to care for their families, and their work and career,” ACOG President Dr. Camille A. Clare said in the organization’s own release. “Menopause is a normal and natural stage of life, but that doesn’t mean that women must suffer through the symptoms without help.”
The headline shift: how hormone therapy is framed
Hormone therapy itself isn’t new, and ACOG supported it in 2014 too. What changed is the emphasis. The 2014 guidance pushed doctors toward “the lowest effective dose for the shortest time.” The 2026 update instead calls for individualized, ongoing decision-making, and it explicitly allows continuing hormone therapy past age 60 for some patients managing persistent symptoms. That detail comes from the New York Times’ own reporting on the guideline, relayed here through NPR affiliate WUSF’s coverage of the same release.
Dr. Catherine Cansino, who chairs ACOG’s Committee on Clinical Practice Guidelines and co-authored the update, told NPR the real change “is the breadth of options that we now have,” which lets doctors take a more individualized approach per patient. Her co-author, Dr. Robert Kauffman, said at a press briefing that hormone therapy is “probably the best option for symptomatic, newly menopausal women within 10 years of the final menstrual period or before the age of 60.”
ACOG also addressed where the caution around hormone therapy originally came from. A 2002 Women’s Health Initiative study linked hormone therapy to higher risk of heart disease, breast cancer, stroke, and blood clots, and that finding shaped two decades of cautious prescribing. According to NPR’s reporting, researchers later found the study’s participants were mostly 60 or older, which made it a poor fit for women in their 40s and early 50s who are actually going through perimenopause. ACOG’s new guidance says the safety of hormone therapy for younger, newly menopausal women is now “well-established.”
None of this means hormone therapy is right for everyone. ACOG is explicit that it isn’t recommended for women with certain risk factors, including a history of blood clots, stroke, or some cancers. The guideline calls for shared decision-making between a patient and her doctor that weighs symptoms, age, personal and family medical history, and individual risk for cardiovascular disease, breast cancer, and blood clots.
New non-hormonal options are part of the guidance now
For women who can’t or don’t want to take hormones, the updated guideline names two newer non-hormonal drugs: fezolinetant (brand name Veozah, FDA-approved in 2023) and elinzanetant (brand name Lynkuet, FDA-approved in 2025). Both work by blocking specific brain signals involved in regulating body temperature and sleep-wake cycles, per WUSF’s reporting. Gabapentin is also named as an option for women who can’t tolerate hormones. ACOG frames these as treatments for symptoms, not cures. The guideline doesn’t specify individual doses. That’s a conversation for a patient and her own doctor.
The guideline also lists non-drug approaches, including cognitive behavioral therapy, mindfulness-based practices, exercise, clinical hypnosis, and acupuncture. ACOG’s own wording treats these as adjuncts that tend to work best alongside medical treatment, not replacements for it. One category explicitly didn’t make the cut: plant-based estrogens and herbal supplements, which ACOG says still have no solid evidence behind them for safety or effectiveness, and which aren’t FDA-regulated for purity.
What this means if you’re navigating menopause right now
This is reported as what a major medical organization changed in its official guidance, not a to-do list. If you’re dealing with hot flashes, sleep disruption, or mood changes tied to perimenopause or menopause, the people equipped to say whether any of this applies to you are your own OB-GYN or doctor, who knows your health history, your risk factors, and your symptoms. This article can’t assess any of that for you.
Since sleep disruption is one of the three symptom categories this update addresses, our guide to gentle bedtime stretches for a calmer wind-down covers a low-risk habit some women use alongside whatever their doctor recommends.
A note on what this article is, and isn’t
This article summarizes a newly published clinical guideline. It is not medical advice, and it is not a recommendation to start, stop, or change any medication or treatment, hormonal or otherwise. Talk to your OB-GYN or doctor about what applies to your own health history before making any decisions about menopause symptom treatment.
Sources: American College of Obstetricians and Gynecologists (“ACOG Expands Recommendations for Management of Menopause Symptoms,” Oct. 15, 2026), WUSF/NPR (“Hot flashes, night sweats, insomnia — OB-GYNs set new rules for menopause treatment,” Oct. 16, 2026), MedicalXpress (“Menopause hormone therapy gets stronger endorsement from OB-GYNs in expanded guideline,” Oct. 16, 2026).